Nazione: Stati Uniti
Lingua: inglese
Fonte: NLM (National Library of Medicine)
HUMAN C1-ESTERASE INHIBITOR (UNII: 6KIC4BB60G) (HUMAN C1-ESTERASE INHIBITOR - UNII:6KIC4BB60G)
CSL Behring GmbH
HUMAN C1-ESTERASE INHIBITOR
HUMAN C1-ESTERASE INHIBITOR 500 [iU] in 10 mL
BERINERT is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients. The safety and efficacy of BERINERT for prophylactic therapy have not been established. BERINERT is contraindicated in individuals who have experienced life-threatening hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations. Risk Summary Background risk (general population) A review of available data suggests that major birth defects occur in 2-4% of the U.S. general population and that miscarriage occurs in 15-20% of clinically recognized pregnancies, regardless of drug exposure. Data Risk in BERINERT patients In a retrospective case collection study, 20 pregnant women ranging in age from 20 to 35 years received BERINERT with repeated doses up to 3,500 IU per HAE attack; these women reported no complications during delivery and no harmful effects on their 34 neonates
Each product presentation includes a package insert and the following components: Storage and Handling
Biologic Licensing Application
BERINERT- HUMAN C1-ESTERASE INHIBITOR CSL BEHRING GMBH ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BERINERT SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BERINERT. BERINERT [C1 ESTERASE INHIBITOR (HUMAN)] FOR INTRAVENOUS USE. FREEZE-DRIED POWDER FOR RECONSTITUTION. INITIAL U.S. APPROVAL: 2009 RECENT MAJOR CHANGES Dosage and Administration (2.1) 09/2021 INDICATIONS AND USAGE BERINERT is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients. (1) The safety and efficacy of BERINERT for prophylactic therapy have not been established. (1) DOSAGE AND ADMINISTRATION FOR INTRAVENOUS USE ONLY. Store the vial in the original carton in order to protect from light. Store at 2-30°C (36-86°F). Do not freeze. (2) Administer 20 International Units per kg body weight. (2) Reconstitute BERINERT prior to use using the Sterile Water for Injection, USP provided. (2.1) Use the silicone-free syringe provided for administration of BERINERT. (2.1) Administer at room temperature within 8 hours of reconstitution. (2.1) Inject at a rate of approximately 4 mL per minute. (2.2) Do not mix BERINERT with other medicinal products or solutions. (2.2) Appropriately trained patients may self-administer upon recognition of an HAE attack. (2.2) DOSAGE FORMS AND STRENGTHS 500 International Units lyophilized concentrate in a single-dose vial for reconstitution with 10 mL of Sterile Water for Injection, USP. (3) CONTRAINDICATIONS Do not use in patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations. (4) WARNINGS AND PRECAUTIONS Hypersensitivity reactions may occur. Epinephrine should be immediately available to treat any acute severe hypersensitivity reactions following discontinuation of administration. (5.1) Serious arterial and venous thromboembolic ( Leggi il documento completo